SeekPharma
Brand Manager
as a Service
Years of hands-on commercial life-science experience and capabilities as a scalable service. Fully end-to-end.
What we do
One team, three jobs
We plan the brand, create what it runs on, and deliver it to your customers — the same loop a senior in-house team would run, available as a service.
01
Plan
- Brand plan, end-to-end
- Insight generation
- Omnichannel plan
- Strategic workshops
- Gap analysis
- Desk research
02
Create
- Marketing materials, all in one: detail aid, email campaigns, leave-behinds, digital and analogue
- Omnichannel by default
- Concept and visualisation
- Reference and claim management
- Approval, e.g. Veeva PromoMats
03
Deliver
- Cycle meetings, end-to-end
- Commercial advisory boards
- Speaker tours
- Educational formats
- Launch events
- Sales training
- Objection handling
- Logistics
How we help
Built around how you actually need help
Four situations we hear most from pharma and biotech teams in Switzerland — and what we do about each one.
Legacy & resource allocation
Keep your established brands moving
When priorities shift to new products or indications, your legacy brands keep earning revenue but stop getting attention — and budget is too tight to hire for it. We take over their day-to-day commercial management so your in-house team can concentrate on what's strategic, without your legacy brands losing share of voice.
Market entry
Capacity that scales with your launch
A Swiss launch needs different capacity at every stage — from pre-launch research through soft launch to post-approval scaling, in both marketing and the field. We staff the launch window at full strength, then release the capacity once it's no longer needed. You keep authorisation, regulatory and access; we take the commercial track.
18–24m before approvalSoft launch
~180 daysLaunch
First 6m+ post approval
6 mo.
The first six months set the trajectory for the years that follow — we put full capacity into the launch window, then release it.
47%
of EMA-approved medicines were fully available in Switzerland in 2024, down from 64% in 2018.
Rare disease
means low prevalence and high cost of acquisition — we reach small, dispersed populations with people who've done it before.
Source: Interpharma, Health Panorama 2025
AI readiness
A seat at the AI model table
Physicians increasingly ask or spar with AI models about therapy decisions, guidelines or comparisons — and act on what they're shown. We generate unbranded scientific content and place it where it gets crawled and read: your own channels, and earned placements on guideline platforms and medical-society sites.
In-field support
Field coverage, on demand
Coverage gaps from absences, or secondary segments that never get visited, rarely justify a new hire. We supply experienced KAMs for specific tasks and time periods, train and accompany your existing field force, and prepare territories through landscaping and opt-in generation.
Profiles
Who we are
Rahul Habibur
- MSc in Pharma, ETH / Harvard Medical School
- MBA at IMD Lausanne
076 482 49 11
Naveed Khan
- MSc in Pharma, ETH / Harvard Medical School
079 460 18 19
Our joint experience
Launches
- Oncology: endometrial cancer launch, 2021
- Respiratory: launch of 2 novel asthma therapies, 2021
- Rare drug-induced brain bleedings: pre-launch, 2024
Therapy areas
- Oncology: uncommon gynaecological tumours
- Brand management in rheumatology
- Further therapeutic experience in pulmonary arterial hypertension, haematology & gastroenterology
Leadership
- Leading teams, both line and matrix
- P&L responsibility for budgets of up to CHF 6m
Companies
Our ask
Let's do a pilot
Pick one brand and one deliverable — a cycle campaign, a segmentation, or a region of field coverage. We fix a scope, and let our work speak for itself.
Rahul Habibur
076 482 49 11
Naveed Khan
079 460 18 19